At its monthly meeting, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed two ongoing safety reviews.

More information on all safety reviews currently under evaluation is provided in the table below. The Committee did not start or conclude a referral.

The PRAC also focused on the broad range of its responsibilities which cover all aspects of the risk management of the use of medicines. Information on all topics discussed by the PRAC is available below in the agenda for the meeting. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next PRAC meeting at the beginning of February.

Posted on the EMA website on 13 January 2017